Optimizing Cardiovascular Outcomes in Diabetes Mellitus

American Journal of Medicine

Volumn 120, Issue 9 SUPPL. 2, 2007, Pages

  Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Diabetes mellitus; Insulin sensitizer; Macrovascular disease; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; AMILORIDE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; PIOGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYMPTOM; CHRONIC INFLAMMATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MECHANISM; DYSLIPIDEMIA; EDEMA; ENDOTHELIAL DYSFUNCTION; FIBRINOLYSIS; HEART FAILURE; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; LIFE EXPECTANCY; LOW DRUG DOSE; MICROANGIOPATHY; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCREENING; SELF MONITORING; SURVIVAL;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 34548420967     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2007.07.002     Document Type: Article

References (65)

1. Thom T., Haase N., Rosamond W., et al., American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the AHA Statistics Committee and Stroke Statistics Subcommittee. Circulation 113 (2006) e85-e151
2. Stamler J., Vaccaro O., Neaton J.D., and Wentworth D. Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16 (1993) 434-444
3. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complicat 15 (2001) 44-54
4. Kannel W.B., and McGee D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care 2 (1979) 120-126
5. Ho J.E., Paultre F., and Mosca L. Is diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women?. Data from the Women's Pooling Project. Stroke 34 (2003) 2812-2816
6. McCarron P., Greenwood R., Elwood P., et al. The incidence and aetiology of stroke in the Caerphilly and Speedwell Collaborative Studies II: risk factors for ischaemic stroke. Public Health 115 (2001) 12-20
7. Huxley R., Barzi F., and Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 332 (2006) 73-78
8. Roper N.A., Bilous R.W., Kelly W.F., Unwin N.C., and Connolly V.M. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 332 (2001) 1389-1393
9. Ito H., Harano Y., Suzuki M., et al. Risk factor analyses for macrovascular complication in nonobese NIDDM patients: Multiclinical Study for Diabetic Macroangiopathy (MSDM). Diabetes 45 suppl 3 (1996) S19-S23
10. Asakawa H., Tokunaga K., and Kawakami F. Comparison of risk factors of macrovascular complications: peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients. J Diabetes Complicat 14 (2000) 307-313
11. Haffner S.M., Lehto S., Ronnemaa T., Pyörälä K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
12. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularization. JAMA 293 (2005) 1501-1508
13. Ashfaq S., Ghazzal Z., Douglas J.S., Morris D.C., Veledar E., and Weintraub W.S. Impact of diabetes on five-year outcomes after vein graft interventions performed prior to the drug-eluting stent era. J Invasive Cardiol 18 (2006) 100-105
14. Wannamethee G., Whincup P.H., Shaper A.G., Walker M., and MacFarlane P.W. Factors determining case fatality in myocardial infarction: "who dies in a heart attack"?. Br Heart J 74 (1995) 324-331
15. Chun B.Y., Dobson A.J., and Heller R.F. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 20 (1997) 704-708
16. Miettinen H., Lehto S., Salomaa V., et al., FINMONICA Myocardial Infarction Register Study Group. Impact of diabetes on mortality after the first myocardial infarction. Diabetes Care 21 (1998) 69-75
17. de Groote P., Lamblin N., Mouquet F., et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 25 (2004) 656-662
18. de Jong G., van Raak L., Kessels F., and Lodder J. Stroke subtype and mortality: a follow-up study in 998 patients with a first cerebral infarct. J Clin Epidemiol 56 (2003) 262-268
19. Donnan P.T., Boyle D.I., Broomhall J., et al. Prognosis following first acute myocardial infarction in type 2 diabetes: a comparative population study. Diabet Med 19 (2002) 448-455
20. Libby P., and Plutzky J. Diabetic macrovascular disease: the glucose paradox?. Circulation 106 (2002) 2760-2763
21. Cersosimo E., and DeFronzo R.A. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 22 (2006) 423-426
22. Rumble J.R., Cooper M.E., Soulis T., et al. Vascular hypertrophy in experimental diabetes: role of advanced glycation end products. J Clin Invest 99 (1997) 1016-1027
23. Portik-Dobos V., Anstadt M.P., Hutchinson J., Bannan M., and Ergul A. Evidence for a matrix metalloproteinase induction/activation system in arterial vasculature and decreased synthesis and activity in diabetes. Diabetes 51 (2002) 3063-3068
24. Death A.K., Fisher E.J., McGrath K.C., and Yue D.K. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168 (2003) 263-269
25. Marfella R., D'Amico M., Esposito K., et al. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55 (2006) 622-632
26. Sobel B.E., and Schneider D.J. Platelet function, coagulopathy, and impaired fibrinolysis in diabetes. Cardiol Clin 22 (2004) 511-526
27. Kohler P.H., and Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342 (2000) 1792-1801
28. McGill J., Schneider D., Arfken C., Lucore C., and Sobel B. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 43 (1994) 104-109
29. Sobel B.E., Woodcock-Mitchell J., Schneider D.J., Holt R.E., Marutsuka K., and Gold H. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence. Circulation 97 (1998) 2213-2221
30. Pandolfi A., Cetrullo D., Polishuck R., et al. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects. Arterioscler Thromb Vasc Biol 21 (2001) 1378-1382
31. Vasudevan A.R., Burns A., and Fonseca V.A. The effectiveness of intensive glycemic control for the prevention of vascular complications in diabetes mellitus. Treat Endocrinol 5 (2006) 273-286
32. Adiels M., Olofsson S.O., Taskinen M.R., and Boren J. Diabetic dyslipidemia. Curr Opin Lipidol 17 (2006) 238-246
33. Verges B. New insight into the pathophysiology of lipid abnormalities in type 2 diabetes. Diabetes Metab 31 (2005) 429-439
34. Dichtl W., Nilsson L., Goncalves I., et al. Very low-density lipoprotein activates nuclear factor-κB in endothelial cells. Circ Res 84 (1999) 1085-1094
35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
36. Adler A.I. Treating high blood pressure in diabetes: the evidence. Semin Vasc Med 2 (2002) 127-137
37. Jandeleit-Dahm K., and Cooper M.E. Hypertension and diabetes. Curr Opin Nephrol Hypertens 11 (2002) 221-228
38. Kempler P. Learning from large cardiovascular clinical trials: classical cardiovascular risk factors. Diabetes Res Clin Pract 68 suppl 1 (2005) S43-S47
39. Mogensen C.E. New treatment guidelines for a patient with diabetes and hypertension. J Hypertens Suppl 21 (2003) S25-S30
40. Hansson L., Zanchetti A., Carruthers S.G., et al., HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
41. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
42. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus. Arch Intern Med 165 (2005) 1410-1419
43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
44. Collins R., Armitage J., Parish S., Sleigh P., Peto R., and Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361 (2003) 2005-2016
45. Colhoun H.M., Betteridge D.J., Durrington P.N., et al., CARDS Investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
46. Costa J., Borges M., David C., and Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 332 (2006) 1115-1124
47. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
48. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342 (2000) 381-389
49. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
50. Nathan D.M., Cleary P.A., Backlund J.Y., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643-2653
51. Standl E., Balletshofer B., Dahl B., et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 39 (1996) 1540-1545
52. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 18 (1995) 258-268
53. Stratton I.M., Adler A.I., Neil H.A., et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
54. Settler C., Allemann S., Juni P., et al. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 152 (2006) 27-38
55. American Diabetes Association. Standards of medical care in diabetes-2006. Diabetes Care 29 suppl 1 (2006) S4-S42
56. Fonseca V., Desouza C., Asnani S., and Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25 (2004) 153-175
57. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
58. Inzucchi S.E., Masoudi F.A., Wang Y., et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28 (2005) 1680-1689
59. Sauer W.H., Cappola A.R., Berlin J.A., and Kimmel S.E. Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 97 (2006) 651-654
60. Inzucchi S.E., Maggs D.G., Spollett G.R., et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338 (1998) 867-873
61. Chu N.V., Kong A.P.S., Kim D.D., et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 25 (2002) 542-549
62. Dormandy J.A., Charbonnel B., Eckland D.J., et al., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
63. Erdman E., Dormandy J.A., Charbonnel B., Massi-Bendetti M., Moules I.K., Skene A.M., and PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive study. [slide presentation] (2005). http://www.proactive-results.com/ahappt/AHA_files/frame.htm Presented at the American Heart Association meeting; November 16, Dallas, TX. Available at: http://www.proactive-results.com/ahappt/AHA_files/frame.htm Accessed January 17, 2007.
64. Wilcox R.G., Bousser M.G., Betteridge D.J., et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38 (2007) 865-873
65. Mudaliar S., Change A.R., and Henry R.R. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocr Pract 9 (2003) 406-416